|
|
La Jolla Pharmaceutical Company - Company Profile Snapshot
| Company Profile: |
La Jolla Pharmaceutical Company |
| Ticker: |
LJPC |
| Exchanges: |
NAS |
| 2007 Sales: |
n/a |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
86 |
Business Description
La Jolla Pharmaceutical Company. The Group's principal activity is to conduct research and development of therapeutics for the treatment of certain life-threatening antibody-mediated diseases. The diseases include autoimmune conditions such as systemic lupus erythematosus and antibody-mediated stroke that are caused by abnormal B cell production of antibodies that attach healthy tissues. The current therapies for these autoimmune disorders target the symptoms of the diseases or nonspecifically suppress the normal operation of the immune system. The Group's strategy is to Collaborate with pharmaceutical companies to access their research, drug development, manufacturing, marketing and financial resources. On January 11, 2006, The Group announced that would initiate a multi-dose clinical study of Riquent in lupus patients to evaluate the ability of higher doses of Riquent to further reduce antibodies to double stranded DNA.
|
Not the Report you are looking for? Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
